Youcare Pharmaceutical (SH:688658) 智通财经网·2026-01-30 10:38Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -280 million to -235 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Financial Performance - The company anticipates a net profit loss for 2025, contrasting with the previous year's statutory disclosure data [1] - The adjustment in pricing and sales strategy for the product "Ginkgo Biloba Extract Injection" at the end of 2024 is expected to have a substantial phased impact on the company's revenue and profit [1] Strategic Adjustments - The company is committed to a long-term development strategy, continuously adjusting and improving its operational strategies to enhance efficiency [1] - Efforts are being made to optimize sales strategies and maintain the stability of core sales channels, thereby continuously strengthening the company's core competitiveness and investment value [1] Research and Development - During the reporting period, the company maintained a high proportion of investment in research and development, with R&D expenses increasing year-on-year [1] - The high level of R&D investment has had a certain impact on the company's net profit [1]